IDO Antibody (mIDO-48): sc-53978

IDO Antibody (mIDO-48) is a rat monoclonal IgG2b antibody that detects Indoleamine 2,3-dioxygenase (IDO) in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). Anti-IDO antibody (mIDO-48) is available in both non-conjugated and multiple conjugated forms, such as agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and various Alexa Fluor® conjugates. Indoleamine 2,3-dioxygenase plays a crucial role in immune regulation by catalyzing the degradation of the essential amino acid L-tryptophan into N-formylkynurenine, a process that is vital for modulating T cell responses and maintaining immune tolerance. IDO′s activity is particularly important in the context of pregnancy, as IDO helps protect the developing fetus from maternal immune rejection by creating a local immunosuppressive environment. Additionally, IDO′s expression can inhibit T cell proliferation, which has implications for cancer immunotherapy and autoimmune diseases, making IDO a significant target for therapeutic intervention. The gene encoding human IDO is located on chromosome 8p12-p11, and IDO′s modulation through pharmacological or genetic means may provide strategies for controlling undesirable T cell responses in various clinical settings.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IDO Antibody (mIDO-48) References:

1. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses.  |  Mellor, AL., et al. 2002. J Immunol. 168: 3771-6. PMID: 11937528
2. HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity.  |  Logan, GJ., et al. 2002. Immunology. 105: 478-87. PMID: 11985668
3. Molecular cloning, sequencing and expression of human interferon-gamma-inducible indoleamine 2,3-dioxygenase cDNA.  |  Dai, W. and Gupta, SL. 1990. Biochem Biophys Res Commun. 168: 1-8. PMID: 2109605
4. IDO-GCN2 and autophagy in inflammation.  |  McGaha, TL. 2015. Oncotarget. 6: 21771-2. PMID: 26317232
5. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.  |  Munn, DH. and Mellor, AL. 2016. Trends Immunol. 37: 193-207. PMID: 26839260
6. IDO activation, inflammation and musculoskeletal disease.  |  Ogbechi, J., et al. 2020. Exp Gerontol. 131: 110820. PMID: 31884118
7. IDO/kynurenine pathway in cancer: possible therapeutic approaches.  |  Abd El-Fattah, EE. 2022. J Transl Med. 20: 347. PMID: 35918736
8. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.  |  Fujiwara, Y., et al. 2022. Cancer Treat Rev. 110: 102461. PMID: 36058143
9. IDO Activity Involved in the Pathogenesis and the Treatment of Inflammation- induced Diseases.  |  Reininghaus, E., et al. 2022. Curr Top Med Chem. 22: 2106. PMID: 36482738
10. CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma.  |  Xu, X., et al. 2024. Cancer Res. 84: 2123-2140. PMID: 38635903
11. Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12-->p11 by fluorescent in situ hybridization.  |  Najfeld, V., et al. 1993. Cytogenet Cell Genet. 64: 231-2. PMID: 8404046
12. Prevention of allogeneic fetal rejection by tryptophan catabolism.  |  Munn, DH., et al. 1998. Science. 281: 1191-3. PMID: 9712583

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IDO Antibody (mIDO-48) has 22 citations in a variety of scientific publications.

Primary antibodies like Anti-IDO Antibody (mIDO-48) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IDO Antibody (mIDO-48) Specifications

Alternate Product Name: IDO

Product Clone Name: mIDO-48

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b

Amino Acids:

Epitope Target: IDO

Epitope Species: mouse

Product Reactivity/Detection: IDO

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2b in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 22 citations in various scientific publications

Available Conjugates/Forms for IDO Antibody (mIDO-48): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin